Future of Pulmonary Hypertension Care in India (From Imports to 'Atmanirbhar' Innovation), Pg18

Key Highlights:

• In 2026, Pulmonary Hypertension (PH) care in India is shifting towards precision and accessibility.
• India has become a global hub for affordable PH therapy, manufacturing drugs like Endothelin Receptor Antagonists (ERAs) and PDE5 inhibitors.
• The Union Budget 2026 accelerated domestic biologic production via the 'Biopharma SHAKTI' initiative, committing ₹10,000 crore.
• ABDM 2.0 (Ayushman Bharat Digital Mission) facilitates patient-controlled health records for seamless monitoring.
• Trials indicate yoga as a supportive therapy improving the quality of life for Pulmonary Arterial Hypertension (PAH) patients.

Detailed Insights:

• Historically, diagnosis of PH in India was delayed due to misdiagnosis with asthma or fatigue.
• Domestic manufacturing and customs duty exemptions are reducing the financial burden on patients.
• The 'Biopharma SHAKTI' initiative aims to make advanced therapies accessible within India, reducing reliance on expensive imports.
• ABDM 2.0 enables efficient monitoring of patient progress across different locations, enhancing healthcare delivery.
• Indian researchers are pioneering integrative PH care, incorporating holistic wellness practices like yoga.
• Despite progress, challenges persist in rural infrastructure, affecting access to timely diagnosis and treatment.

Key Concepts Involved:

• Pulmonary Hypertension (PH): High blood pressure in the arteries of the lungs, straining the heart.
• Endothelin Receptor Antagonists (ERAs): Medications that block the effects of endothelin, a substance that narrows blood vessels.
• PDE5 inhibitors: Drugs that relax muscles in the lungs and increase blood flow.
• Ayushman Bharat Digital Mission (ABDM): Government initiative to create a digital health ecosystem.